Overview

A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of doxorubicin plus sorafenib versus doxorubicin plus placebo in patients with advanced hepatocellular carcinoma (HCC).
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Treatments:
Doxorubicin
Liposomal doxorubicin
Niacinamide
Sorafenib